A Phase I Open-Label Multicenter Study of FT596 as a Monotherapy and in Combination with Rituximab or Obinutuzumab in Subjects with Relapsed/Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non-hodgkin Lymphoma, Unspecified
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Histologically documented lymphomas expected to express CD19 and CD20 including: Grade 1-3b FL; marginal zone lymphoma; transformed indolent NHL; Richter transformation with DLBCL morphology and with absolute lymphocyte count <5000/µL; DLBCL; primary mediastinal B-cell lymphoma; small lymphocytic lymphoma; or mantle cell lymphoma. 2) Relapsed/refractory disease following prior systemic immunochemotherapy regimen who have no available curative treatment options and who have limited prognosis (<2 years’ survival) with currently available therapies. 3) At least one bi-dimensionally measurable lesion, e.g., nodal lesion >1.5 cm in longest dimension or extra-nodal lesion >1.0 cm in longest dimension by computed tomography (CT) scan.

You may not be eligible for this study if the following are true:

  • 1) Females who are pregnant or breastfeeding. 2) Eastern Cooperative Oncology Group (ECOG) Performance Status =2. 3) Receipt of any biological therapy, chemotherapy, or radiation (except palliative radiation, rituximab, or obinutuzumab) within 2 weeks prior to Day 1 or five half-lives, whichever is shorter; or any investigational therapy within 28 days prior to Day 1. 4) Receipt of an allograft organ transplant.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.